Tonix Pharmaceuticals CEO buys 5,000 common shares

Q: How many TNXP shares did Seth Lederman buy?

Seth Lederman purchased 5,000 TNXP common shares at $4.055 per share on November 11, 2026, leaving him with 16,005 directly held shares. The purchase was not reported as made under a Rule 10b5-1 plan.

Q: How many TNXP shares did Seth Lederman hold after the purchase?

His directly held position afterward was 16,005 shares. Reported indirect positions were 20,001 shares through an IRA account and 1 share through Lederman & Co.; a footnote says he may be deemed a control person of the entity.

Available on EDGAR 11/12/2026 - 08:01 AM EST Accepted by SEC EDGAR 11/12/2026 - 08:00 AM EST

Filing Impact

(High)

Filing Sentiment

(Positive)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Tonix Pharmaceuticals Holding Corp. (TNXP) Chief Executive Officer Seth Lederman purchased 5,000 common shares at $4.055 per share on November 11, 2026. His directly held position afterward was 16,005 shares. Reported indirect positions include 20,001 shares through an IRA account and 1 share through Lederman & Co.; a footnote says Lederman may be deemed a control person of the entity.

Insider Trade Summary

Net Buyer: 5,000 shares

Net Buy 1 txn

Insider LEDERMAN SETH

Role Chief Executive Officer

Bought 5,000 shs ($20K)

Increase in Position 45.4%

Type	Security	Shares	Price	Value
Purchase	Common Stock, $0.001 par value	5,000	$4.055	$20K
Holding	Common Stock, $0.001 par value ^F1	--	--	--
Holding	Common Stock, $0.001 par value ^F1	--	--	--

Holdings After Transaction: Common Stock, $0.001 par value — 16,005 shares (Direct); Common Stock, $0.001 par value — 20,001 shares (Indirect, By IRA Account); Common Stock, $0.001 par value — 1 share (Indirect, Lederman & Co.)

Holdings Before and After: Common Stock, $0.001 par value, 11,005 to 16,005 shares (Direct)

Footnotes (1)

F1. Reporting person may be deemed a control person of this entity.

Key Figures

Shares purchased: 5,000 shares Purchase price: $4.055 per share Direct position afterward: 16,005 shares +2 more

5 metrics

Shares purchased 5,000 shares November 11, 2026

Purchase price $4.055 per share November 11, 2026 purchase

Direct position afterward 16,005 shares November 11, 2026

Indirect position through IRA account 20,001 shares November 11, 2026

Indirect position through Lederman & Co. 1 share November 11, 2026

Key Terms

control person, par value, Rule 10b5-1 plan

3 terms

control person regulatory

"may be deemed a control person of this entity"

A control person is an individual or entity that can significantly influence a company’s decisions and direction through ownership, voting power, or contractual rights—think of them as the captain who can steer the ship. Investors care because a control person’s choices affect corporate strategy, board appointments, and transactions that can raise or lower a stock’s value, and they often carry additional legal responsibilities and disclosure requirements to protect other shareholders.

par value financial

"Common Stock, $0.001 par value"

Par value is the fixed amount printed on a bond or stock that represents its original value when issued. It’s like the face value of a coin or bill—what the issuer promises to pay back or the starting price of a stock—though it often doesn’t change with market prices. It matters because it helps determine certain financial details, like how much the company will pay back at maturity.

Rule 10b5-1 plan regulatory

"not reported as made under a Rule 10b5-1 plan"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many TNXP shares did Seth Lederman buy?

Seth Lederman purchased 5,000 TNXP common shares at $4.055 per share on November 11, 2026, leaving him with 16,005 directly held shares. The purchase was not reported as made under a Rule 10b5-1 plan.

How many TNXP shares did Seth Lederman hold after the purchase?

His directly held position afterward was 16,005 shares. Reported indirect positions were 20,001 shares through an IRA account and 1 share through Lederman & Co.; a footnote says he may be deemed a control person of the entity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LEDERMAN SETH

(Last)

(First)

(Middle)

C/O TONIX PHARMACEUTICALS HOLDING CORP.

200 CONNELL DRIVE, SUITE 3100

(Street)

BERKELEY HEIGHTS

NEW JERSEY

07922

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Tonix Pharmaceuticals Holding Corp. [ TNXP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock, $0.001 par value	11/11/2026		P		5,000	A	$4.055	16,005	D
Common Stock, $0.001 par value								20,001	I	By IRA Account⁽¹⁾
Common Stock, $0.001 par value								1	I	Lederman & Co.⁽¹⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Reporting person may be deemed a control person of this entity.

	/s/ Seth Lederman	11/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR